Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections
Public ClinicalTrials.gov record NCT00761215. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to determine the oral dosage of TR-701 to be used in Phase III studies in patients with complicated skin and skin structure infections.
Study identification
- NCT ID
- NCT00761215
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Enrollment
- 192 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 17, 2008 (Actual)
- Primary completion
- Feb 24, 2009 (Actual)
- Completion
- Feb 24, 2009 (Actual)
- Last update posted
- Nov 25, 2019
2008 – 2009
United States locations
- U.S. sites
- 12
- U.S. states
- 5
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Trius Study Site #011 | Dothan | Alabama | 36301 | — |
| Trius Study site #001 | Chula Vista | California | 91911 | — |
| Trius Study Site #009 | Long Beach | California | 92708 | — |
| Trius Study site #002 | Oceanside | California | 92056 | — |
| Trius Study site #010 | Pasadena | California | 91105 | — |
| Trius Study site 007 | San Francisco | California | 94143 | — |
| Trius Study site 003 | San Jose | California | 95124 | — |
| Trius Study site 004 | Columbus | Georgia | 31904 | — |
| Trius Study site #006 | Ludowici | Georgia | 31316 | — |
| Trius Study site #005 | Savannah | Georgia | 31406 | — |
| Trius Study site #012 | Springfield | Illinois | 62701 | — |
| Trius study sie #008 | Detroit | Michigan | 48202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00761215, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 25, 2019 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00761215 live on ClinicalTrials.gov.